Bioverativ (NASDAQ:BIVV) was downgraded by research analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a report issued on Monday, The Fly reports.

Other research analysts also recently issued reports about the stock. Credit Suisse Group reaffirmed a “neutral” rating and issued a $65.00 target price on shares of Bioverativ in a research report on Thursday. Zacks Investment Research downgraded shares of Bioverativ from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Jefferies Group raised their price objective on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank of Canada raised their price objective on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a research report on Thursday. Finally, Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Bioverativ has a consensus rating of “Hold” and a consensus price target of $62.53.

Bioverativ (NASDAQ BIVV) traded up $1.36 during midday trading on Monday, hitting $64.11. 829,100 shares of the company were exchanged, compared to its average volume of 999,962. The stock has a market cap of $11,230.00 and a P/E ratio of 15.67. Bioverativ has a 1 year low of $40.99 and a 1 year high of $65.09.

Bioverativ (NASDAQ:BIVV) last posted its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.25. The firm had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm’s revenue for the quarter was up 27.2% compared to the same quarter last year. analysts expect that Bioverativ will post 2.69 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in BIVV. Wells Fargo & Company MN acquired a new stake in shares of Bioverativ in the 3rd quarter worth $124,500,000. Woodford Investment Management Ltd acquired a new stake in shares of Bioverativ in the 3rd quarter worth $85,455,000. Jackson Square Partners LLC acquired a new stake in shares of Bioverativ in the 3rd quarter worth $99,336,000. Old Mutual Global Investors UK Ltd. acquired a new stake in shares of Bioverativ in the 3rd quarter worth $96,827,000. Finally, ValueAct Holdings L.P. acquired a new stake in shares of Bioverativ in the 3rd quarter worth $72,514,000. Institutional investors own 96.04% of the company’s stock.

WARNING: “Bioverativ (BIVV) Downgraded by Piper Jaffray Companies” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/bioverativ-bivv-downgraded-by-piper-jaffray-companies/1818532.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

The Fly

Analyst Recommendations for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.